The Friday biotech signal
Capacity gets funded. Specialized work surges.
A major GMP build, an expanded cardiovascular label, an ADC partnership, registrational funding, and early clinical evidence all point back to the teams that turn milestones into execution.
JobReports original editorial image
953
Active biopharma jobs added
104
Biopharma employers
+89.5%
Versus last Friday
191
Commercial & business roles
This dated issue is part of the public report archive. See the service update for account availability.
Drug delivery / Future GMP capacity
Evonik commits more than CAD 150 million to Vancouver capacity
Evonik announced a new GMP drug-product facility for lipid-based delivery in Vancouver, backed by up to CAD 68 million from Canada's Strategic Response Fund. The company says the build will provide more than three times the manufacturing capacity of its current site.
The plan also adds quality-control and microbiological-testing capability for clinical release work. Production is scheduled to begin at the end of 2029, making this a funded future expansion—not capacity that is operating today.
Why it matters
A multi-year GMP build concentrates future work across process engineering, validation, quality control, microbiology, automation, tech transfer, and regulatory readiness. Evonik did not publish a hiring count, so this is a capability signal rather than a claim about open roles today.
Metabolic medicine / FDA label
Mounjaro adds a cardiovascular-risk indication
Lilly announced FDA approval for Mounjaro to lower the risk of cardiovascular death, non-fatal heart attack, or non-fatal stroke in adults with type 2 diabetes at high cardiovascular risk.
SURPASS-CVOT established non-inferiority to Trulicity for the composite endpoint; superiority was not established. The added label reaches medical, regulatory, safety, market-access, and commercial teams, without establishing new hiring.
Oncology / Platform deal
Genentech licenses DualityBio's next-generation ADC programs
DualityBio will lead discovery and early global clinical work on ADCs built with its DUPAC payload platform. Genentech receives worldwide licenses and assumes further development and commercialization after Phase 1a.
The agreement includes a $45 million upfront payment and more than $1 billion in potential aggregate milestones. Those milestones are contingent—not committed revenue or a broad hiring forecast.
Hepatitis B / Registrational funding
AusperBio closes a $120 million Series C
AusperBio says the financing will support AHB-137 through its chronic-hepatitis-B Phase 3 program and commercialization readiness, while also advancing AHB-171 and combination approaches.
Registrational execution can focus clinical, regulatory, CMC, quality, evidence, and launch-planning work. AHB-137 remains investigational, and the company did not announce a hiring plan.
Colorectal cancer / Early clinical data
InxMed publishes randomized KRAS G12C combination data
InxMed announced publication in The Lancet Oncology of Phase Ib/II results for oral ifebemtinib plus garsorasib in previously treated KRAS G12C-mutant metastatic colorectal cancer.
The 36-patient randomized portion reported response and progression-free-survival signals favoring the combination, but the PFS confidence interval included 1. The early evidence supports more development, not definitive benefit or approval.
Friday volume nearly doubles
JobReports added 953 active biotechnology and pharmaceutical opportunities from 104 employers between midnight Eastern and today's cutoff. That is about 89.5% above the comparable Friday window one week earlier. Commercial and business work led the named role families, followed by clinical and medical roles.
These are active opportunities first captured by JobReports before cutoff, not employer-supplied posting times. Role-family and location classifications are directional.
61
U.S.-remote roles
21
North Chicago roles
14
Boston roles
Editor's shortlist
Five roles worth a closer look
Senior Scientist, Biology
South San Francisco, California
Process Engineer II - GMP Equipment Lifecycle
Seattle, Washington
Clinical Trial Manager
Waltham, Massachusetts
Director, Analytical Development & Quality Control
Watertown, Massachusetts
Senior Systems Engineer
Portland, Oregon
The takeaway
Scale and specialization are moving together.
Facility investment, an expanded label, licensed ADC programs, registrational funding, and early clinical evidence all put a premium on disciplined execution. Today's verified openings carry that pattern into biology, GMP engineering, clinical operations, analytical quality, and laboratory automation.